What did the FDA just approve for advanced breast cancer?

On Sept. 18 the FDA approved Eli Lilly’s Inluriyo-Verzenio pill combination for advanced ER-positive, HER2-negative breast cancer carrying an ESR1 mutation — a specific genetic profile an oncologist tests for. In a 159-patient late-stage trial, the combo held the cancer at bay for a median 11.1 months versus 5.5 months on Inluriyo alone. The tradeoff is real: severe diarrhea and low white-blood-cell counts are among the risks, so this is a doctor-patient decision, not a headline to act on alone. What matters: it’s a targeted approval for a defined mutation — the way modern cancer drugs earn their place, one biomarker at a time.